journal article·2026-03

Integrating clinical challenges and nanotechnological based approaches for psoriasis therapy

Ana Vitoria Pupo Silvestrini, Ualisson José da Silva, Milena Finazzi Morais, Lívia Vieira Depieri, Maria Vitória Lopes Badra Bentley

Publisher page

Abstract

Psoriasis is a chronic, inflammatory, immune-mediated, papulosquamous skin disease with diverse clinical phenotypes. It is frequently associated with cardiometabolic and rheumatologic comorbidities, as well as significant physical and psychological impact, accounting for the fourth largest global burden of disability. Conventional topical and systemic drug therapies constitute the basis of therapeutic protocols; however, their efficacy in alleviating the symptoms, decrease recurrence or resolving inflammation is limited by predominantly single-target mechanisms and pharmacokinetic challenges imposed by extra- and intracellular barriers. In this review, we discuss recent breakthroughs in understanding psoriasis's pathological targets and immunopathogenic mechanisms. Simultaneously, several materials with multifunctional properties have emerged, constituting innovative drug delivery systems, such as nanoparticles and microneedles, specifically designed to improve topical drug delivery, allow precise targeting within the lesion and combination therapies. We highlight the importance of the design and composition of these formulations to improve therapeutic efficacy and their evolution in the administration of various agents, from conventional drugs and natural compounds to therapeutic nucleic acids. To place these advances in a broader context, we integrate recent insights into immunopathogenesis and clinical heterogeneity with material-driven design, demonstrating how nanosystems and microneedles can complement conventional therapies and support the application of emerging multi-targeted approaches. The innovations discussed here open new avenues for optimizing treatment satisfaction and highlight the potential of nanotechnology-driven strategies to revolutionize psoriasis treatment. However, challenges remain in translating these technologies into clinical practice.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Psoriasis: Treatment and Pathogenesis · Acne and Rosacea Treatments and Effects

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. The global challenge for skin health10.1111/bjd.13854 ↗
2. Global skin disease morbidity and mortality10.1001/jamadermatol.2016.5538 ↗
3. The burden of skin and subcutaneous diseases: findings from the global burden of disease study 2019
4. World Health Organization · 2016
5. A systematic review of worldwide epidemiology of psoriasis10.1111/jdv.13854 ↗
6. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study
7. Global burden and future trends in psoriasis epidemiology: insights from the global burden of disease study 2019 and predictions to 203010.1007/s00403-024-02846-z ↗
8. Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender10.1111/bjd.19169 ↗
9. Psoriasis and comorbid diseases10.1016/j.jaad.2016.07.064 ↗
11. Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study10.1111/bjd.15021 ↗
12. A narrative review of the socioeconomic burden associated with generalised pustular psoriasis10.1111/exd.14841 ↗
13. Prevalence, incidence, mortality and healthcare resource use for generalized pustular psoriasis, palmoplantar pustulosis and plaque psoriasis in England: a population-based cohort study10.1093/bjd/ljae217 ↗
14. Guidelines of care for the management of psoriasis and psoriatic arthritis10.1016/j.jaad.2010.11.055 ↗
15. The impact of psoriasis on health care costs and patient work loss10.1016/j.jaad.2008.06.043 ↗
16. The burden of moderate to severe psoriasis10.2165/11591580-000000000-00000 ↗
17. Pathophysiology, clinical presentation, and treatment of psoriasis10.1001/jama.2020.4006 ↗
19. Clinical translation of long-acting drug delivery formulations10.1038/s41578-021-00405-w ↗
20. Engineering precision nanoparticles for drug delivery10.1038/s41573-020-0090-8 ↗
21. Nanotechnology-based strategies against SARS-CoV-2 variants10.1038/s41565-022-01174-5 ↗
22. Nanoparticles in the clinic: an update10.1002/btm2.10143 ↗
23. Evolution of drug delivery systems: from 1950 to 2020 and beyond10.1016/j.jconrel.2021.12.030 ↗
24. Nanotechnology approaches for global infectious diseases10.1038/s41565-021-00866-8 ↗
25. Immunotherapeutic nanoparticles: from autoimmune disease control to the development of vaccines10.1016/j.bioadv.2022.212726 ↗
26. Nanocarriers for skin applications: where do we stand?10.1002/anie.202107960 ↗
27. Microneedle biomedical devices10.1038/s44222-023-00141-6 ↗
28. Psoriasis
29. The clinical spectrum of psoriasis10.1016/j.clindermatol.2007.08.003 ↗
30. Erythrodermic psoriasis: pathophysiology and current treatment perspectives10.2147/PTT.S101232 ↗
31. Antistreptococcal treatment of psoriasis: a systematic review10.1007/s00403-024-03051-8 ↗
32. Antistreptococcal interventions for guttate and chronic plaque psoriasis
33. Inverse psoriasis: from diagnosis to current treatment options10.2147/CCID.S189000 ↗
34. Palmoplantar psoriasis10.1016/j.clindermatol.2016.09.004 ↗
35. Generalized pustular psoriasis: a review and update on treatment10.1111/jdv.14949 ↗
36. Pathophysiology of generalized pustular psoriasis10.1111/exd.14768 ↗
37. “Autoinflammatory psoriasis”—genetics and biology of pustular psoriasis10.1038/s41423-020-0519-3 ↗
39. Approach to managing patients with nail psoriasis10.1111/j.1468-3083.2009.03364.x ↗
40. Differential risks of psoriatic arthritis development in patients with varied psoriasis manifestations: a sex- and ethnicity-specific analysis10.3389/fmed.2024.1385491 ↗
41. High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a cross-sectional study10.1007/s00296-013-2876-z ↗
42. The pathogenesis of psoriatic arthritis10.1016/S0140-6736(18)30830-4 ↗
43. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience10.1093/rheumatology/keg384 ↗
44. The risk of mortality in patients with psoriasis10.1001/archderm.143.12.1493 ↗
45. The prevalent Comorbidome at the onset of psoriasis diagnosis10.1007/s13555-023-00986-0 ↗
46. Generalized pustular psoriasis: a nationwide population-based study using the National Health Data System in France10.1111/jdv.19901 ↗
47. Internalized stigma in psoriasis: a multicenter study10.1111/1346-8138.13841 ↗
48. Prevalence of anxiety, depression, sleeping problems, cognitive impairment, and suicidal ideation in people with autoimmune skin diseases10.1016/j.jpsychires.2024.06.024 ↗
49. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and Meta-analysis10.1038/jid.2013.508 ↗
50. Psoriasis and suicidality: a systematic review and meta-analysis10.1016/j.jaad.2017.05.019 ↗
51. The psychosocial adaptation of patients with skin disease: a scoping review10.1186/s12889-019-7775-0 ↗
52. Role of stress in skin diseases: a neuroendocrine-immune interaction view10.1016/j.bbi.2023.12.005 ↗
53. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K10.1111/j.1365-2133.2010.09941.x ↗
54. Psoriasis increased the risk of adverse cardiovascular outcomes: a new systematic review and Meta-analysis of cohort study
55. Trends in mortality and cause-specific mortality among patients with psoriasis and psoriatic arthritis in Ontario, Canada10.1016/j.jaad.2020.10.031 ↗
56. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review10.1111/j.1365-2133.2007.08068.x ↗
57. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies10.1016/j.jaad.2012.08.015 ↗
58. Psoriasis in liver disease: associations beyond nonalcoholic fatty liver disease10.1016/j.jaad.2021.03.023 ↗
59. Increase in comorbidities with age among patients with psoriatic arthritis: a multicenter observational study10.1007/s00296-024-05760-9 ↗
60. Association of Psoriasis with Incident Venous Thromboembolism and Peripheral Vascular Disease10.1001/jamadermatol.2021.4918 ↗
61. Autonomic dysfunction and cardiovascular risk in psoriatic arthritis10.1007/s10067-022-06484-6 ↗
62. Prevalence and phenotype of concurrent psoriasis and inflammatory bowel disease10.1097/MIB.0000000000001169 ↗
63. Psoriasis, psoriaticarthritis and increased risk of incident Crohn’s disease in US women10.1136/annrheumdis-2012-202143 ↗
64. Association of Psoriasis with Inflammatory Bowel Disease10.1001/jamadermatol.2018.3631 ↗
65. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study10.1111/bjd.14528 ↗
66. Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease—a systematic review and Meta-analysis10.1093/ecco-jcc/jjz152 ↗
67. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci10.1016/j.ajhg.2012.02.020 ↗
68. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis10.1001/jamadermatol.2020.0024 ↗
69. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies10.1111/jdv.12165 ↗
70. Association of Psoriasis with the risk of developing or dying of Cancer: a systematic review and Meta-analysis10.1001/jamadermatol.2019.3056 ↗
71. Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants10.1038/ncomms15382 ↗
72. The immunogenetics of psoriasis: a comprehensive review10.1016/j.jaut.2015.07.008 ↗
73. Characteristics and pathogenesis of Koebner phenomenon
74. Drug-induced psoriasis: clinical perspectives10.2147/PTT.S126727 ↗
75. Type1 interferons potential initiating factors linking skin wounds with psoriasis pathogenesis
76. The immunology of psoriasis—current concepts in pathogenesis10.1007/s12016-024-08991-7 ↗
77. Skin immune sentinels in health and disease10.1038/nri2622 ↗
78. The inflammatory response in psoriasis: a comprehensive review10.1007/s12016-016-8535-x ↗
79. Induction of IL-17+ T cell trafficking and development by IFN-γ: mechanism and pathological relevance in psoriasis10.4049/jimmunol.181.7.4733 ↗
80. Dynamic changes in resident and infiltrating epidermal dendritic cells in active and resolved psoriasis10.1016/j.jid.2016.11.033 ↗
81. IL-23 from Langerhans cells is required for the development of Imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing γδ T cells10.1038/jid.2014.98 ↗
82. Chemokine receptors in the pathogenesis and therapy of psoriasis10.1016/j.jdermsci.2011.11.007 ↗
83. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis10.1038/jid.2009.65 ↗
84. The IL-17 family of cytokines in health and disease10.1016/j.immuni.2019.03.021 ↗
85. Keratinocyte overexpression of IL-17C promotes Psoriasiform skin inflammation10.4049/jimmunol.1201505 ↗
86. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis10.1038/nature05505 ↗
87. Human T H 9 cells are skin-tropic and have autocrine and paracrine Proinflammatory capacity10.1126/scitranslmed.3007828 ↗
88. Clinically resolved psoriatic lesions contain psoriasis-specific IL-17–producing αβ T cell clones10.1172/JCI93396 ↗
89. Oxidative stress involvement in psoriasis: a systematic review10.1080/10715762.2019.1648800 ↗
90. Interleukin-36–receptor antagonist deficiency and generalized pustular psoriasis10.1056/NEJMoa1013068 ↗
91. Chronopharmacology of glucocorticoids10.1016/j.addr.2019.02.004 ↗
92. Immune regulation by glucocorticoids10.1038/nri.2017.1 ↗
93. Topical corticosteroids in psoriasis: strategies for improving safety10.1111/j.1468-3083.2009.03358.x ↗
94. Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities10.1111/j.1468-3083.2012.04522.x ↗
95. Vitamin D analogs: therapeutic applications and mechanisms for selectivity10.1016/j.mam.2008.04.001 ↗
96. Vitamin D: a master example of nutrigenomics10.1016/j.redox.2023.102695 ↗
97. Pharmacological effects of vitamin D and its analogs: recent developments10.1016/j.drudis.2014.06.008 ↗
98. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis10.1067/mjd.2002.120942 ↗
99. A cellular atlas of calcineurin signaling10.1016/j.bbamcr.2022.119366 ↗
100. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies10.1016/j.jaad.2008.12.032 ↗